Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association

Ndumele, Chiadi E., Rangaswami, Janani, Chow, Sheryl L., Neeland, Ian J., Tuttle, Katherine R., Khan, Sadiya S., Coresh, Josef, Mathew, Roy O. +22 more·2023·Circulation
DOI 10.1161/cir.0000000000001184

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status
    Ricardo Correa‐Rotter, Peter R Rossing, Maria Eugênia Canziani, Maria Luiza Caramori, David Z.I. Cherney, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku et al. · 2026 · Kidney International Reports
  2. Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular–kidney–metabolic stage progression: a real-world cohort study
    Jheng‐Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu‐Min Lin · 2026 · Diabetes Research and Clinical Practice
  3. Associations of Biological Age and Heart Age Accelerations With New‐Onset Stroke in Individuals With Cardiovascular‐Kidney‐Metabolic Syndrome Stages 0–3: Evidence From a Chinese Longitudinal Study
    Hao Zhu, Hannah Lui, Li He, Jing Zhang, Zhi Jin · 2026 · Journal of Clinical Hypertension
  4. Uncovering core diseases in temporal trajectories of cardiovascular-kidney-metabolic (CKM) syndrome in UK Biobank: network-based study
    Xinyang Long, Mingli Li, Dantong Li, Zengnan Mo · 2026 · Scientific Reports
  5. Prevalence of cardiovascular-kidney-metabolic syndrome in areas of Southern China where ethnic minority populations reside: a cross-sectional study
    Kehui Li, Ying Zeng, Man-Qiu Mo, Yunan Xu, X B Li, Yuanshan Xu, Zhiqiang Nong, Ling Pan, Rongjie Huang · 2026 · Frontiers in Endocrinology
  6. From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
    Jens Juul Holst · 2026 · Biological Psychiatry
  7. Comorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry
    Juan Pablo Arango-Ibañez, Sebastián Seni-Molina, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodríguez, Andrea Valencia, Mario Miguel Barbosa, Luis Eduardo Echeverría, Adrián J. Lescano, Juan Pablo Allende, Tessa Negrín Valdés et al. · 2026 · Journal of the American Heart Association
  8. Dapagliflozin ameliorates high-fat diet–induced, megalin-mediated autolysosomal dysfunction in proximal tubules via suppression of megalin-dependent endocytosis
    Kazuya Takemoto, Michihiro Hosojima, Hideyuki Kabasawa, Koichi Komochi, Hiroyuki Aoki, Nanako Sugita, Sawako Goto, Ryohei Kaseda, Satoru Nagatoishi, Kouhei Tsumoto et al. · 2026 · American Journal of Physiology-Renal Physiology
  9. Dynamic associations of BMI-metabolic phenotype transitions with incident cardiovascular disease in middle-aged and elderly adults: a longitudinal cohort study
    Yuhan Zhao, Jiawei Li, Yiqun Miao, Rongrong Guo, Yuan Luo, Huiying Wang, Namuna Dallakoti, Ying Wu · 2026 · BMC Cardiovascular Disorders
  10. Social Risk Factors and Disparities in Advanced Cardiovascular-Kidney-Metabolic Syndrome
    Obinna Ikechukwu Ekwunife, X W Wang, Raphael André Fraser, Alexander Yunke, Jennifer Annette Campbell, Rebekah J. Walker, Leonard E. Egede · 2026 · JAMA Network Open
  11. Challenges and knowledge gaps in sex differences in cardio–kidney–metabolic syndrome across the lifespan
    Aline M. A. de Souza, Alexandra Kautzky‐Willer, Damian G. Romero, Licy L. Yanes Cardozo, Sofia Bano Ahmed, Samar Rezq · 2026 · Biology of Sex Differences
  12. Longitudinal associations of cumulative and repeated-measure patterns of insulin resistance surrogate indices with biological age acceleration and incident cardiovascular disease across cardiovascular-kidney-metabolic syndrome stages 0–3: evidence from CHARLS 2011–2020
    Shu-Shu Han, Qin Liu, Min-Qi Zhou, Yun Liu, Tingting Guo, Yue-Kang Hu, Teng-Ao Gao, Zhi-Ming Zeng · 2026 · Cardiovascular Diabetology
  13. Renal-diabetic overlap in pulmonary arterial hypertension
    Matteo Toma, Suela Vani, Giulio Savonitto, Francesca Coppi, Andrea Garascia, Alberto Giannoni, Clara Hjalmarsson, Francesco Lo Giudice, Carlo Lombardi, Claudia Raineri et al. · 2026 · Heart
  14. Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease
    Katherine R. Tuttle, George L. Bakris, Florian M.M. Baeres, Casper N. Bang, Willem A. Bax, Nicolas Belmar, Derrick Musinga, David Z.I. Cherney, Gil Chernin, Soo Kun Lim et al. · 2026 · Journal of the American College of Cardiology
  15. Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
    Keith Louis Saum, Subramaniam Pennathur, Jenny E. Kanter · 2026 · Circulation Research
  16. Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review
    Eirini Stamouli, Christina Trakatelli, Maria Sarigianni, Konstantinos Kitsios, Vasilios Kotsis · 2026 · Cardiovascular Diabetology
  17. Clinical characteristics and outcomes of diabetic ketoacidosis in patients with type 2 diabetes during acute systemic stress
    Rania Al Sayed Abd Albaky Mohamed, Laila Mahmoud Ali Hendawy, Eman Farghaly, Amr Mahmoud Mohamed Saleh · 2026 · Cardiovascular Diabetology – Endocrinology Reports
  18. Progression of Cardiovascular–Kidney–Metabolic Syndrome among Hispanic/Latino Adults in the United States
    Pooja Kondeti, Amitava Chakrabarti, Yelena R. Drexler, Robert A. Mesa, Julien O. Tremblay, Linda C. Gallo, James Phillip Lash, Sylvia E. Rosas, Nora Franceschini, Daniele Massera et al. · 2026 · Clinical Journal of the American Society of Nephrology
  19. Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome
    Jingyi Gong, Nicholas Chiu, Kimberly Clinch, Yunzhe Qian, Jennifer E. Ho, Rishi K. Wadhera · 2026 · Journal of the American College of Cardiology
  20. Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop
    Lesley H. Curtis, David E Arterburn, Sengwee Toh, Jingchuan Serena Guo, Miguel Ángel Hernán, Esti Iturralde, Ania M. Jastreboff, Kristina Henderson Lewis, Jennifer Leigh Lund, Matthew L. Maciejewski et al. · 2026 · Annals of Internal Medicine
  21. Gaps, Barriers, and Facilitators to Implementing Comprehensive Medication Management in Cardiovascular‐Kidney‐Metabolic Care: A Qualitative Study
    Omolayo Umaru, Deborah L. Pestka, Lindsay A. Sorge, CHI-HAN CHENG, Kate Dryden, Janani Rangaswami, Katherine R. Tuttle, Amanda R. Brummel, Joshua J. Neumiller, Wendy L. St. Peter · 2026 · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
  22. Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular–kidney–metabolic stages 0–3: a prospective cohort study
    Ningning Xue, Letong Ma, Ziwen Zhou, Tiantian Bai, Xianjie Jia, Xing Wei · 2026 · Cardiovascular Diabetology
  23. Cardiovascular Risk Reduction With GLP-1 RA Drugs
    Marie Pigeyre, Hertzel C. Gerstein · 2026 · Circulation
  24. The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process
    Luz Maria Quirino-Vela, Miguel Angel Mayoral-Chávez, Carlos Alberto Matias‐Cervantes, Yobana Pérez-Cervera, Iván Antonio García-Montalvo, Juan José Alpuche · 2026 · Frontiers in Endocrinology
  25. Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
    Javier Crespo, Paula Iruzubieta, Tomas de Vega, José Luís Calleja · 2026 · Medicina Clínica
  26. Serum uric acid to creatinine ratio as marker of early vascular damage and renal tubular injury in non-albuminuric diabetic kidney disease
    Maurizio Di Marco, Sabrina Scilletta, Nicoletta Miano, Nicola Marrano, Annalisa Natalicchio, Francesco Giorgino, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Roberto Scicali, Andrea Tumminia et al. · 2026 · Journal of Endocrinological Investigation
  27. Combined podocyte, fibrotic and echocardiographic correlates of an operationally defined subclinical cardiorenal phenotype in chronic kidney disease: an exploratory study
    Nilufar Akhmedova, Тухтаев Достонбек Ашурович, Bakhodir Narziev, Akmal Ismoilov, Maftuna Juraeva, Gulomjon Kholov, Ulugbek Ochilov · 2026 · Renal Failure
  28. Cardiovascular-Kidney-Metabolic Syndrome Staging and Cancer Risk
    Xixi Xiao, Jiayong Li, Yu Ning, Yunyao Yang, Zhen Ou, Bin Dong, Yugang Dong, Yi Li, Chen Liu, Yilong Wang et al. · 2026 · JACC CardioOncology
  29. Baseline, repeated-measure burden, and two-time-point patterns of the triglyceride-glucose index-visceral lipid ratio (TyG-VLR) and incident cardiovascular disease in cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3: a longitudinal China Health and Retirement Longitudinal Study (CHARLS) analysis
    AoMen Lu, Hao Jie Han, Qian Xu, Shuang-Ke Bai · 2026 · Cardiovascular Diabetology
  30. Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025
    Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne M. Carson, Cade Shadbolt, Brendon Lange Neuen, Clare Gabrielle Arnott, Andrew J. Wilson, Min Jun, Nicole L. Pratt et al. · 2026 · British Journal of Clinical Pharmacology
  31. Scaling integrated cardiovascular–kidney–metabolic care through primary health care in the Americas: a health policy analysis of HEARTS 2.0 implementation levers and architecture
    Pedro Ordúñez, Jarbas Barbosa da Silva · 2026 · The Lancet Regional Health - Americas
  32. Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis
    Tobin Joseph, Chenyi Gao, Ramesh Nadarajah, Riyad Omar Al-Lehebi, Luís Alves, David D. Berg, Amy Couper, Indranil Datta, Loay Eleyan, Mohammad Haris et al. · 2026 · EClinicalMedicine
  33. Lifestyle and Metabolic Health, Low-Grade to Clinically Elevated Albuminuria, and Cardiovascular-Renal Diseases
    Yi Ding, Qiuyu Cao, Xianglin Wu, Youjin Jiang, Xiaoran Li, Yu Xu, Min Xu, Tiange Wang, Yuhong Chen, Zhiyun Zhao et al. · 2026 · JACC Asia
  34. Joint association between FIB-4 index and advanced cardiovascular-kidney-metabolic syndrome with aortic valve calcification: a community cohort in China
    Yunteng Fang, Jiayi Shen, Junqiu Zhao, Xingwei Wei, Qiwen Huang, Guanyu Niu, Zhilin Wang, Haoxiang Xu, Xuan Wang, Yuesong Pan et al. · 2026 · Acta cardiologica. Supplementum
  35. Clonal haematopoiesis and cardiovascular-kidney-metabolic syndrome: a cohort study
    Annie C. Y. Chang, Linke Li, Daniel Ezzat, Spencer Flynn, Nore De Moor, Jan Hemeryck, Niekbachsh Mohammadnia, Art Schuermans, Zhi Yu, Yixuan Liu et al. · 2026 · European Heart Journal
  36. Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee
    Evgeny V. Shlyakhto, G. P. Arutyunov, Alina Yu. Babenko, Sergey Anatol'evich Boytsov, Виллевальде Светлана Вадимовна, Ivan Ivanovich Dedov, Oksana M. Drapkina, Елиашевич Софья Олеговна, Н. Э. Звартау, Vladimir T Ivashkin et al. · 2026 · Russian Journal of Cardiology
  37. HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America
    Eiran Z. Gorodeski, Gregg C. Fonarow, P Goyal, Faraz S. Ahmad, Nancy M. Albert, Michelle Weisfelner Bloom, Biykem Bozkurt, Khadijah K Breathett, Spencer J. Carter, Richard K. Cheng et al. · 2026 · Journal of Cardiac Failure
  38. Laboratory methods and quality assurance in the National Longitudinal Study of Adolescent to Adult Health Waves V and VI
    Timothy B. Plante, Eric A. Whitsel, Allison E. Aiello, Lauren M. Gaydosh, Robert A. Angel, Robert A. Hummer, J. Grago, Kathleen Mullan Harris, Rebekah H. Boyle, Mary Cushman · 2026 · The Journals of Gerontology Series B
  39. Comprehensive Centers of Excellence for Women’s Cardiovascular Care: A Science Advisory From the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine
    Natalie A. Cameron, Sadiya S. Khan, C. Noel Bairey Merz, LaPrincess C. Brewer, Matthew M. Davis, Erin Poe Ferranti, William A. Grobman, Afshan B. Hameed, Tamara S. Hannon, Robert A. Harrington et al. · 2026 · Circulation
  40. Software-driven chronic disease management: Algorithm design and implementation in a community-based blood pressure control pilot
    Rahul C. Deo, Rebecca K. Smith, Calum A. MacRae, Esha Price, Horace Sheffield, Rahul S. Patel · 2024 · SAGE Open Medicine
  41. In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality
    Doreen Zhu, William Guy Herrington · 2024 · Annals of Internal Medicine
  42. Semaglutide cuts kidney risk in obesity
    Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Katherine Esposito · 2024 · Journal of Endocrinological Investigation
  43. Glucosuria as a major mechanism-associated effect of sodium-glucose cotransporter 2 inhibitors: Is there cause for concern?
    Tatiana Yu. Demidova, M. Ya. Izmaylova · 2024 · Meditsinskiy sovet = Medical Council
  44. Obstructive sleep apnea and chronic kidney disease: time to move from association to causality and intervention
    Patrick J. Hanly, Sofia Bano Ahmed · 2024 · SLEEP
  45. Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model
    Phil C. McEwan, VOLKER FOOS, Geraint M. Roberts, Robert L. Jenkins, Marc Evans, David Collins. Wheeler, Jieling Chen · 2025 · Diabetes Obesity and Metabolism
  46. Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
    Jincheng Shen, Amara Sarwal, Ravinder Singh, Sydney Elizabeth Hartsell, Guo Wei, McKenna R. Nevers, Jesse C. Christensen, Augustine Takyi, Niharika Katkam, Catherine G. Derington et al. · 2025 · Diabetes Obesity and Metabolism
  47. The prevalence of chronic kidney disease in people with severe mental illness: A systematic review protocol
    Claire Carswell, Kate Bramham, Joseph Chilcot, Rowena Jacobs, David Osborn, Najma Siddiqi · 2025 · PLoS ONE
  48. Lipid Biomarkers and Cardiometabolic Diseases: Critical Knowledge Gaps and Future Research Directions
    Hyun Suk Yang · 2025 · Metabolites
  49. Association and Prognostic Implications of Peripheral Arterial Disease and Calcific Aortic Stenosis
    M. Faure, Jérôme Jouan, Philippe Lacroix, Jean-David Blossier, Pierre‐Marie Preux, Lucie Chastaingt, Marouane Boukhris, M. Cané, G. Lux, Victor Aboyans et al. · 2024 · Journal of the Heart Valve Society
  50. Management of Dyslipidemia in Chronic Kidney Disease
    Deepak Vedamurthy, Usman Sagheer, Akruti Patel, Gurnoor Singh, Dinesh Kumar Kalra · 2025 · Current Cardiovascular Risk Reports
  51. Impact of Cardiovascular–Kidney–Metabolic Syndrome Staging on Myocardial Infarction Outcomes: A Retrospective Analysis of 2.7 Million Patients
    Ronny Shabtai, Marlon Villaga Gatuz, Adam Folman, Maguli S Barel, Rami Abu‐Fanne, Dmitry Abramov, Mamas A. Mamas, Ariel Roguin, Ofer M. Kobo · 2025 · Diseases
  52. Aortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study.
    Ashkan Abdollahi, Maryam Mojarrad Sani, M. Shabani, B. S. Matuck, M. Blaha, Colin O. Wu, B. Ambale-Venkatesh, M. Budoff, J. Strom, Jerome I. Rotter et al. · 2025 · European journal of internal medicine
  53. A novel high dimensional approach to assess heterogeneous treatment effect in claims data
    Tiansheng Wang, Virginia Pate, Richard Wyss, John B. Buse, Michael R. Kosorok, Til Stürmer‎ · 2025 · American Journal of Epidemiology
  54. Atherosclerotic Cardiovascular Disease Risk Estimates Using the New Predicting Risk of Cardiovascular Disease Events Equations: Implications for Statin Use
    Asma Rayani, Garima V. Sharma, Jared Alexander Spitz · 2025 · Current Cardiology Reports
  55. GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease
    Helena Sardà, Idoia Genua, Inka Miñambres · 2025 · Medicina Clínica (English Edition)
  56. Comparison of Globorisk, SCORE2, and PREVENT in the Stratification of Cardiovascular Risk and its Relationship with End‐Organ Damage Among Adults With Arterial Hypertension
    Silvia Palomo‐Piñón, Luis Antonio Alcocer, Humberto Álvarez‐López, Ernesto Germán Cardona-Muñóz, Adolfo Chávez‐Mendoza, Enrique Díaz‐Díaz, José Manuel Enciso‐Muñoz, Héctor Galván‐Oseguera, Martín Rosas-Peralta, Luis Rey Garcia Cortes et al. · 2025 · Journal of Clinical Hypertension
  57. Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function
    Xinyu Zhang, Wei Min Zhou, Hui Liu, Chengquan Zhang, Yifan Qi, Yuan Xiao, Zuyi Yuan, Lizhe Sun, Jianqing She, Bowen Lou · 2025 · Frontiers in Cardiovascular Medicine
  58. Response to Comment on Wang et al. Transition of BMI Status From Childhood to Adulthood and Cardiovascular-Kidney-Metabolic Syndrome in Midlife: A 36-Year Cohort Study. Diabetes Care 2025;48:2045–2053
    Yang Wang, Zheng Liu · 2025 · Diabetes Care
  59. Hypertension in youth with metabolic syndrome
    Jhanahan Sriranjan, Claire Adams, Rahul Chanchlani, Manish D. Sinha · 2025 · Journal of clinical lipidology
  60. The Framingham steatosis index as a predictor of advanced CKM syndrome in US adults: Evidence from NHANES 2001 to 2018
    Fangchun Yang, Xuzhao Gao, Rui Tang, Kang Yang · 2025 · Medicine
  61. Atherosclerotic Cardiovascular Disease Risk Assessment in the Age of PREVENT
    Sumeet Brar, Amit Chakrabarti, Eugene Yang · 2025 · Current Epidemiology Reports
  62. From 1990 to 2021, the burden of diabetes among the elderly in the Western Pacific Region (WPR) and projections for 2040 prevalence: A systematic analysis of the 2021 Global Burden of Disease study
    Yve Han, Huaxing Lou, Peng Zhao, Hui Li, Congyi Zhang, Hongru Sun · 2025 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  63. Association of Obesity with Kidney Function Outcomes in Heart Failure with Preserved Ejection Fraction
    Lixia Deng, Hocine Tighiouart, Tatsufumi Oka, Marcelle L. Tuttle, Brian C. Downey, Ethan J. Rowin, Jennifer E. Ho, Mark J. Sarnak, Wendy I. McCallum · 2026 · Kidney360
  64. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
    Jonathan Paul Mochel, Jessica L. Ward, Thomas Blondel, Debosmita Kundu, Maria M. Merodio, Claudine Zemirline, Emilie Guillot, Ryland T. Giebelhaus, A. Paulina de la Mata, Chelsea A. Iennarella‐Servantez et al. · 2023 · Research Square
  65. When Chronic Kidney Disease (CKD) Intersects with Heart Failure: Insights and Implications of the Identification of KDIGO-Defined CKD in 1.4 Million U.S. Veterans with Heart Failure
    Bertram Pitt, Patrick Rossignol · 2024 · European Journal of Heart Failure
  66. Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic Health
    Jonathan Paul Mochel · 2024 · Preprints.org
  67. Cardiovascular-kidney-metabolic syndrome predicted the risks of geriatric syndromes and mortality of major chronic diseases
    Meng Hao, Hui Zhang, Yi Li, Jingyi Wu, Zixin Hu, Shuai Jiang, Aijun Sun, Jin Li, Xiaofeng Wang · 2024 · Research Square
  68. The Potential of Dietary Strategies: The Impact of Low-Carbohydrate Diet on Cardiovascular-Kidney-Metabolic Syndrome
    Zhuoxing Li, Xiunan Liu, Xin Ma, Mao Xiao, Xue Zhang, Yanyi Deng, Hao Liu, Yun Sun, Xiang Xiao · 2025 · medRxiv
  69. Cardiovascular-Kidney-Metabolic Syndrome in China
    Meihan Guo · 2025 · JACC Asia
  70. The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025
    Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne M. Carson, Cade Shadbolt, Brendon Lange Neuen, Clare Gabrielle Arnott, Andrew J. Wilson, Min Jun, Nicole L. Pratt et al. · 2025 · medRxiv
  71. VESALIUS and the Anatomy of High-Risk Prevention
    Chiadi E. Ndumele, Roger Scott Blumenthal · 2025 · New England Journal of Medicine
  72. Interleukin-6 and the inflammatory origins of chronic kidney disease
    Annie Chang, Niekbachsh Mohammadnia, Michael C. Honigberg · 2026 · European Journal of Preventive Cardiology
  73. Realizing the Real-World Benefits of Cardiovascular-Kidney-Metabolic Therapies: Leveraging Data Science and AI
    Chiadi E. Ndumele, Jay B. Lusk, Sadiya S. Khan · 2026 · Circulation Population Health and Outcomes
  74. Cardio-renal–metabolic management and incident atrial fibrillation: charting the way
    Janice Y. Chyou, Andrea M. Russo, Jonathan Paul Piccini · 2026 · European Heart Journal
  75. Primary Care: Its Pokemon Moment
    Bryan N. Becker · 2024 · The American Journal of Medicine
  76. Associations between Diabetes-Specific Medication Regimen Complexity and Cardiometabolic Outcomes among Underserved Non-Hispanic Black Adults Living with Type 2 Diabetes Mellitus
    Cheryl Wisseh, Edward K. Adinkrah, Linda Opara, Sheila Melone, Emem Udott, Mohsen Bazargan, Magda A. Shaheen · 2024 · Pharmacy
  77. Clinical effectiveness of amlodipine/indapamide/perindopril fixed-dose combination in patients with metabolic disorders: results of post hoc analyzes of the TRICOLOR study
    Karpov IuA, N. A. Logunova, Boris B. Kvasnikov, Хомицкая Юнона Владиславовна · 2024 · Russian Journal of Cardiology
  78. Patient-Centric Outcomes: A Longitudinal Study on the Impact of Multifaceted Interventions in Diabetes and Cardiovascular Health
    Riyadh Ahmed Alahmdi, Fahad Ahmad Almazyad, Msaad Abdullah Altulihee · 2024 · Journal of Advances and Scholarly Researches in Allied Education
  79. In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level
    Doreen Zhu, William Guy Herrington · 2024 · Annals of Internal Medicine
  80. Physical activity and cardiorenal health—from associations to interventional studies
    Roseanne E Billany, Alice Caroline Smith, Matthew P. M. Graham-Brown · 2024 · Nephrology Dialysis Transplantation
  81. Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
    Kathryn L. Williams, Molly Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka · 2024 · Progress in Pediatric Cardiology
  82. Atherosclerotic Cardiovascular Disease in Cardiovascular–Kidney-Metabolic Syndrome
    Alyssa M. Sanchez, Nikitha M. Murthy, Anastasia Shakhbazova, Roy O. Mathew · 2025 · Cardiology Clinics
  83. A comprehensive impact of GLP1Ras on CKM syndrome
    Yu Horiuchi, Nicholas W. Wettersten, Kengo Tanabe · 2025 · International Journal of Cardiology
  84. The Influence of Body Mass Index on Percutaneous Coronary Intervention Outcomes: A National Inpatient Sample Study
    Eun Seo Kwak, Momin Shah, Abdulmajeed Alharbi, Nahush Roop Bansal, Qutaiba Qafisheh, Shariq Ahmad Wani, Mohanad Qwaider, Ayman Salih, Ahmed El Rahyel, Hafsa Shah et al. · 2025 · Hearts
  85. The Diminished Cardiorespiratory Fitness in Cardiovascular-Kidney-Metabolic Syndrome
    Yuting Liu, Yanting Liang, Huan Ma, Hengyuan Gao, Xinzhou Zhang · 2025 · Journal of Multidisciplinary Healthcare
  86. Neighborhood Walkability and Cardio-Kidney-Metabolic Syndrome: A Narrative Review
    Pedro Rafael Vieira de Oliveira Salerno, ALENA GONZALEZ, Avery Hum, Ariela Baur, Colin P. Carpenter, Mohamed A. A. Bassiony, Vaibhav Shah, Zhuo Chen, Weichuan Dong, Sadeer G Al-Kindi · 2025 · Journal of Vascular Diseases
  87. Understanding Cardiovascular-Kidney-Metabolic Syndrome and the Necessity of a Multidisciplinary Approach
    Inha Jung · 2025 · Korean Journal of Medicine
  88. Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease
    Thelma Barber, Joshua J. Neumiller, Michelle A. Fravel, Robert Lee Page II, Katherine R. Tuttle · 2025 · American Journal of Health-System Pharmacy
  89. Laying the Groundwork for the AHA Health Care by Food Initiative
    Kevin G.M. Volpp, Jen Muse, Stacey Chang, Natalie Privett, Mitchell S.V. Elkind · 2025 · NEJM Catalyst
  90. Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions
    Radica Z. Alicic, Joshua J. Neumiller · 2025 · Cardiology Clinics
  91. Parathyroid Hormone Levels as an Independent Predictor of Ischemic Heart Disease in Stage 3–5 Non-Dialysis Chronic Kidney Disease: A Retrospective Cohort Study
    Suthiya Anumas, Pichaya Tantiyavarong, Pattharawin Pattharanitima · 2025 · Journal of Clinical Medicine
  92. Association between liver fibrosis scores and cardiovascular disease in elderly based on NHANES 1999–2018
    Man K. Du, Yuan Li, Jiangtao Du, Jianqiang Song, Shitao Sun, Wanwan Guo, Lifeng Zhu, Shimian Guo · 2025 · Scientific Reports
  93. Hypertension in South Africa: a growing epidemic and evolving treatment paradigms
    Barney Jordaan, B Theron, Erasmus Labri Owusu, Elmien Bronkhorst · 2025 · South African General Practitioner
  94. Remnant cholesterol in CHARLS: unaddressed dynamic changes and clinical confounders in CKM progression analysis
    Wanhaier Abudoureheman, Fan Zhang, Qiuzi Sun · 2025 · European Journal of Preventive Cardiology
  95. Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome
    Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich · 2025 · Future Cardiology
  96. A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes
    Eugene E. Wright, Ana María Cebrián Cuenca, Daniel Ngui · 2025 · Clinical Diabetes
  97. Longitudinal patterns of postpartum body mass index and their impact on cardiometabolic and renal risk among women with prior gestational diabetes: a prospective cohort analysis
    Zicheng Nie, Wenbo Zhao, Quanmin Jing · 2025 · Frontiers in Endocrinology
  98. Beyond Kidney Genes: Broad Clinical Implications of Genetic Testing for Nephrology Patients
    Naama Elefant, Maddalena Marasà, Hila Milo Rasouly · 2025 · Seminars in Nephrology
  99. Noninvasive Screening for Elevated LVEDP and Health Status in Outpatients at Risk for Heart Failure
    Omar Cantú-Martínez, Andrew A Girard, Weiwei Jin, Derek G. Rinderknecht, Thomas Cheek, John A. Spertus · 2025 · JACC Advances
  100. Stalled progress and emerging disparities in acute myocardial infarction mortality among U.S. older adults (> 65 Years) with renal failure, 1999–2023
    Bazil Azeem, Yumna Fatima, Iffat Ambreen Magsi, Hamza Ali Hasnain Sheikh, Muhammad Umar Qasim, Muhammad Abdullah Naveed, Rabia Asim, Muhammad Basit Azeem, Tazheen Saleh Muhammad, Mata‐e‐Alla Doggar et al. · 2025 · BMC Cardiovascular Disorders